抗MRSA头孢菌素联合达托霉素作为MRSA菌血症初始治疗:是否改善预后?
该回顾性观察研究纳入意大利4家医院2020-2024年465例MRSA血流感染患者,比较抗MRSA头孢菌素联合达托霉素与其他抗菌方案作为初始治疗的效果。
要点
- 抗MRSA头孢菌素联合达托霉素较其他方案降低90天死亡风险(aHR 0.54)。
- 联合治疗组在DOOR分析中更优概率为59.9%(95%CI 52.4%-67.4%)。
- 该联合方案可能作为MRSA血流感染初始治疗的有效选择。
核心结论
- 抗MRSA头孢菌素联合达托霉素可能作为MRSA血流感染的有效初始治疗,尤其适用于不良结局高风险患者。
主要发现
- 90天全因死亡181例(39%),260例(56%)发生至少1种DOOR分析中的不良结局。
- 联合治疗组DOOR分析中获得更好结局的概率为59.9%(95%CI 52.4%-67.4%)。
关键数值与推荐
- 主要终点为90天全因死亡率,采用Cox回归分析并以IPTW验证。
- DOOR评分:持续MRSA感染、持续菌血症≥5天、耐药、不良事件、90天复发各加1分,死亡计7分。
临床怎么用
- 对MRSA血流感染患者,可考虑抗MRSA头孢菌素联合达托霉素作为初始治疗方案,尤其适用于高死亡风险者。
局限性
- 回顾性观察性设计可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The study aim was to evaluate the effectiveness of anti-methicillin-resistant Staphylococcus aureus (MRSA) cephalosporins in combination with daptomycin (anti-MRSA Ceph + DAP) compared to other antimicrobial regimens (OARs) as initial treatment of MRSA bloodstream infection (BSI). METHODS: This retrospective observational study enrolled patients with MRSA-BSI from 1 January 2020 to 31 December 2024 at 4 large Italian hospitals. The primary endpoint was 90-day all-cause mortality. Cox regression was used for primary endpoint analysis; results were confirmed with inverse probability of treatment weighting (IPTW). Treatment efficacy was also assessed using the desirability of outcome ranking (DOOR) approach, assigning 1 additional point beyond recovery for 1 of the following negative outcomes: (i) persistent MRSA infection, (ii) persistent bacteremia (≥5 days), (iii) drug resistance, (iv) any adverse event, and (v) 90-day relapse. A score of 7 was assigned for death at any time point. RESULTS: Overall, 465 patients were enrolled: Median age was 76 (IQR, 61-83) years, 59% male, with a Charlson Comorbidity Index score of 7 (IQR, 4-8). Of them, 50 (11%) and 116 (25%) patients had endocarditis and metastatic infection, respectively. Importantly, 90-day mortality occurred in 181 (39%) patients, while 260 (56%) experienced at least 1 negative outcome included in DOOR analysis. Overall, patients in the anti-MRSA Ceph + DAP arm had a 59.9% (95% CI, 52.4%-67.4%) probability of having a better outcome than those in the OAR arm. Particularly, anti-MRSA Ceph + DAP was associated with reduced mortality (aHR, 0.54 [95% CI, .34-.85]), confirmed after adjustment with IPTW analysis. CONCLUSIONS: Anti-MRSA Ceph + DAP could represent a valid initial therapy for MRSA-BSI, especially in patients with high risk of worse outcomes.
引用
- Bavaro DF, Belati A, Sacchet D, et al. Anti-Methicillin-Resistant Staphylococcus aureus (MRSA) Cephalosporins Plus Daptomycin as Initial Therapy for MRSA Bacteremia: Does a "Hit Hard and Fast" Strategy Improve Outcomes? Clin Infect Dis. 2026. PMID: 42262084. doi:10.1093/cid/ciag228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。